Postoperative statin therapy attenuates the intensity of systemic inflammation and increases fibrinolysis after coronary artery bypass grafting

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 5, 2011, Pages 526-531

  Tetik, Sermin ^a   Ak, Koray ^a   Sahin, Yucel ^a   Gulsoy, Ozkan ^b   Isbir, Selim ^a   Arsan, Sinan ^a   Yardimci, Turay ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Pharmacina Institute   (Turkey)

Author keywords

atorvastatin; CABG; fibrinolysis; inflammatory mediators; systemic inflammatory response syndrome

Indexed keywords

ATORVASTATIN; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRINOLYSIS; HUMAN; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

AGED; CORONARY ARTERY BYPASS; CYTOKINES; FEMALE; FIBRINOLYSIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTOPERATIVE COMPLICATIONS; PYRROLES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80053615963     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610379398     Document Type: Article

References (36)

1. Taylor KM. SIRS-the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 1996 ; 61 (6). 1607-1608 (Pubitemid 26179703)
2. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA. 1995 ; 273 (2). 117-123
3. Ak K, Isbir S, Tekeli A, et al. Presence of lipoprotein lipase S447X stop codon affects the magnitude of interleukin 8 release after cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2007 ; 134 (2). 477-483 (Pubitemid 47088577)
4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis an organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992 ; 101 (6). 1644-1655
5. Picone AL, Lutz CJ, Finck C, et al. Multiple sequential insults cause post-pump syndrome. Ann Thorac Surg. 1999 ; 67 (4). 978-985 (Pubitemid 29238284)
6. Wan S, Marchant A, DeSmet JM, et al. Human cytokine responses to cardiac transplantation and coronary bypass grafting. J Thorac Cardiovasc Surg. 1996 ; 111 (2). 469-477 (Pubitemid 26057427)
7. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997 ; 85 (4). 766-782 (Pubitemid 27418878)
8. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularisation. J Thorac Cardiovasc Surg. 1994 ; 108 (4). 626-635 (Pubitemid 24330237)
9. Stadler J, Bentz BG, Harbrecht BG, et al. Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann Surg. 1992 ; 216 (5). 539-546
10. Sablotzki A, Friedrich I, Holzheimer RG, Kress HG, Werdan K, Silber RE. Prophylactic use of immunoglobulins in cardiac surgery. Sepsis. 1999 ; 3 (3). 247-253 (Pubitemid 30146460)
11. Pan W, Pintar T, Anton J, Lee V, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004 ; 110 (11 suppl 1). II45 - II49
12. Donati MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy on cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000 ; 86 (10). 1128-1130, A6
13. Goyal A, Alexander JH, Hafley GE, et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 ; 83 (3). 993-1001 (Pubitemid 46331832)
14. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol. 2009 ; 31 (1). 127-142
15. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998 ; 279 (20). 1643-1650 (Pubitemid 28248591)
16. Tetik S, Ak K, Asbir S, et al. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clin Appl Thromb Hemost. 2010 ; 16 (2). 189-198
17. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001 ; 104 (13). 1577-1579 (Pubitemid 32917355)
18. Correia LC. Sposito AC, Passos LC, et al. Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q wave acute myocardial function. Am J Cardiol. 2002 ; 90 (2). 162-164 (Pubitemid 34775128)
19. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis-as good as it gets?. N Engl J Med. 2008 ; 352 (1). 73-75
20. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996 ; 24 (7). 1125-1128
21. Giroir BP. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade. Crit Care Med. 1993 ; 21 (5). 780-789 (Pubitemid 23139559)
22. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin 6 family of cytokines and gp130. Blood. 1995 ; 86 (4). 1243-1254
23. Mantovani A. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. Drugs. 1997 ; 54 (suppl 1). 15-23 (Pubitemid 27417393)
24. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular diseases. Curr Drug Targets Inflamm Allergy. 2003 ; 2 (3). 257-265
25. Munford RS. Statins and the acute-phase response. N Engl J Med. 2001 ; 344 (26). 2016-2018 (Pubitemid 32568157)
26. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000 ; 6 (12). 1399-1402 (Pubitemid 32001026)
27. Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis. 2000 ; 149 (1). 111-116 (Pubitemid 30125978)
28. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000 ; 20 (2). 556-562 (Pubitemid 30086117)
29. Essig M, Nguyen G, Prié D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 1998 ; 83 (7). 683-690 (Pubitemid 28462781)
30. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb. 1993 ; 13 (7). 1066-1075 (Pubitemid 23195809)
31. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994 ; 14 (2). 223-229
32. Zavadzki C, Susen S, Richard F, et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis. 2007 ; 195 (2). e117 - e125
33. Morishita E, Asakura H, Saito M, et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis. 2001 ; 154 (1). 203-212 (Pubitemid 32008582)
34. Martínez-Comendador JM, Alvarez JR, Mosquera I, et al. Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery. Eur J Cardiothorac Surg. 2009 ; 36 (6). 998-1005
35. Watanabe R, Wada H, Watanabe Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res. 2001 ; 104 (1). 1-6 (Pubitemid 32918249)
36. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006 ; 118 (2). 205-212 (Pubitemid 43833324)